Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 10/20 | 0.72 |
| ▸ | ESR2 | Q92731 | 8/20 | 0.72 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.65 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.65 |
| ▸ | LMNA | P02545 | 1/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.65 |
| ▸ | PGR | P06401 | 1/20 | 0.65 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.65 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.65 |
| ▸ | AR | P10275 | 1/20 | 0.65 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.65 |
| ▸ | MAPT | P10636 | 1/20 | 0.65 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.65 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.65 |
| ▸ | DRD1 | P21728 | 1/20 | 0.65 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.65 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.65 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.65 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5607945 | 0.88 | ESR1 (0.64) | ESR1ESR2CYP2C9TDP1LMNA | |
| SCHEMBL15427906 | 0.86 | ESR1 (0.69) | ESR1ESR2CYP2C9TDP1LMNA | |
| SCHEMBL12201279 | 0.84 | ESR1 (0.60) | ESR1ESR2CYP2C9TDP1LMNA | |
| SCHEMBL27982158 | 0.84 | ESR1 (0.60) | ESR1ESR2CYP2C9TDP1LMNA | |
| Isobutesrol SCHEMBL5694505 | 0.84 | ESR1 (1.00) | ESR1ESR2CYP2C9TDP1LMNA | |
| SCHEMBL23774423 | 0.83 | ESR1 (0.58) | ESR1ESR2CYP2C9TDP1LMNA | |
| SCHEMBL12835878 | 0.83 | ESR1 (0.58) | ESR1ESR2CYP2C9TDP1LMNA | |
| SCHEMBL12384051 | 0.83 | ESR1 (0.58) | ESR1ESR2CYP2C9TDP1LMNA | |
| SCHEMBL28125000 | 0.83 | ESR1 (0.58) | ESR1ESR2CYP2C9TDP1LMNA | |
| SCHEMBL14411084 | 0.83 | ESR1 (0.58) | ESR1ESR2CYP2C9TDP1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4446310-A1 | METHOD FOR PRODUCING BLOCKED ISOCYANATE COMPOUND AND METHOD FOR PRODUCING ISOCYANATE COMPOUND | Asahi Kasei Kabushiki Kaisha (JP) | 2024-10-16 | — | — | EP | disclosed |
| CN-118382612-A | Method for producing blocked isocyanate compound and method for producing isocyanate compound | 旭化成株式会社 | 2024-07-23 | — | — | CN | disclosed |
| US-20240210827-A1 | PHOTOSENSITIVE RESIN COMPOSITION, METHOD FOR MANUFACTURING CURED RELIEF PATTERN, AND SEMICONDUCTOR APPARATUS | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2024-06-27 | — | — | US | disclosed |
| US-20230384674-A1 | ACTINIC RAY-SENSITIVE OR RADIATION-SENSITIVE RESIN COMPOSITION, RESIST FILM, PATTERN FORMING METHOD, AND METHOD FOR MANUFACTURING ELECTRONIC DEVICE | FUJIFILM CORPORATION (JP) | 2023-11-30 | — | — | US | disclosed |
| US-11829068-B2 | Resist composition, method of forming resist pattern, compound, and resin | TOKYO OHKA KOGYO CO., LTD. (JP) | 2023-11-28 | — | — | US | disclosed |
| US-11822240-B2 | Resist composition and method of forming resist pattern | TOKYO OHKA KOGYO CO., LTD. (JP) | 2023-11-21 | — | — | US | disclosed |
| US-11709427-B2 | Positive resist composition and pattern forming process | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2023-07-25 | — | — | US | disclosed |
| WO-2023106377-A1 | METHOD FOR PRODUCING BLOCKED ISOCYANATE COMPOUND AND METHOD FOR PRODUCING ISOCYANATE COMPOUND | 旭化成株式会社 | 2023-06-15 | — | — | WO | disclosed |
| US-11634386-B2 | Method for producing diphenylsulfone compound | KONISHI CHEMICAL IND. CO. LTD. (JP) | 2023-04-25 | — | — | US | disclosed |
| US-20220306572-A1 | METHOD FOR PRODUCING DIPHENYLSULFONE COMPOUND | KONISHI CHEMICAL IND. CO. LTD. (JP) | 2022-09-29 | — | — | US | disclosed |
| EP-2147909-A1 | METHOD FOR PRODUCTION OF ISOCYANATE USING COMPOSITION COMPRISING CARBAMIC ACID ESTER AND AROMATIC HYDROXY COMPOUND, AND COMPOSITION FOR TRANSPORT OR STORAGE OF CARBAMIC ACID ESTER | Asahi Kasei Chemicals Corporation (JP) | 2010-01-27 | — | — | EP | disclosed |
| US-7534555-B2 | Plating using copolymer | HITACHI GLOBAL STORAGE TECHNOLOGIES NETHERLANDS B.V. (NL) | 2009-05-19 | — | — | US | disclosed |
| US-20090062213-A1 | Small Molecule Inhibitors of PDZ Interactions | ARBOR VITA CORPORATION (US) | 2009-03-05 | — | — | US | disclosed |
| CN-101171254-A | Fused thieno[2,3-B]pyridine and thiazolo[5,4-B]pyridine compounds for inhibiting KSP kinesin activity | SCHERING CORP (US) | 2008-04-30 | — | — | CN | disclosed |
| EP-1871776-A2 | FUSED THIENO[2,3-B]PYRIDINE AND THIAZOLO[5,4-B]PYRIDINE COMPOUNDS FOR INHIBITING KSP KINESIN ACTIVITY | SCHERING CORPORATION (US) | 2008-01-02 | — | — | EP | disclosed |
| US-20060247320-A1 | Compounds for inhibiting KSP kinesin activity | SCHERING CORPORATION | 2006-11-02 | — | — | US | disclosed |
| WO-2006098961-A2 | FUSED THIENO [2, 3-B] PYRIDINE AND THIAZOLO [5, 4-B] PYRIDINE COMPOUNDS FOR INHIBITING KSP KINESIN ACTIVITY | SCHERING CORPORATION (US) | 2006-09-21 | — | — | WO | disclosed |
| US-20020120079-A1 | Method of homo- or co-polymerization of alpha-olefin | SAMSUNG GENERAL CHEMICALS CO., LTD. (KR) | 2002-08-29 | — | — | US | disclosed |
| EP-0187999-A2 | Copolyestercarbonate composition | GENERAL ELECTRIC COMPANY (US) | 1986-07-23 | — | — | EP | disclosed |
| US-4029816-A | ANTIHYPERTENSIVE, DIURETIC, SALURETIC | MERCK & CO., INC. (US) | 1977-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220306572-A1 | METHOD FOR PRODUCING DIPHENYLSULFONE COMPOUND | DHPS, TST, IWS1 | ESR1 3406/4885ESR2 2311/4885CYP2C9 1359/4885 |
| US-11709427-B2 | Positive resist composition and pattern forming process | EWSR1, PARG, VIM | ESR1 653/4885ESR2 1232/4885CYP2C9 4809/4885 |
| US-20090062213-A1 | Small Molecule Inhibitors of PDZ Interactions | PDLIM5, DAB2IP, PSD | ESR1 4631/4885ESR2 3597/4885CYP2C9 4883/4885 |
| US-11634386-B2 | Method for producing diphenylsulfone compound | DHPS, TST, IWS1 | ESR1 3406/4885ESR2 2311/4885CYP2C9 1359/4885 |
| US-20060247320-A1 | Compounds for inhibiting KSP kinesin activity | KIFC1, KIF5B, KIF2C | ESR1 3878/4885ESR2 3495/4885CYP2C9 4769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.